Provided by Tiger Trade Technology Pte. Ltd.

Altimmune, Inc.

3.02
-0.1800-5.63%
Post-market: 3.070.0500+1.66%19:59 EDT
Volume:2.67M
Turnover:8.19M
Market Cap:392.81M
PE:-3.02
High:3.19
Open:3.16
Low:3.02
Close:3.20
52wk High:7.73
52wk Low:2.90
Shares:130.07M
Float Shares:124.00M
Volume Ratio:0.52
T/O Rate:2.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9999
EPS(LYR):-0.9999
ROE:-50.57%
ROA:-28.17%
PB:1.75
PE(LYR):-3.02

Loading ...

Top News Today: Stocks Gain as Economic Data Offsets War Fears

Dow Jones
·
Mar 05

Top News Today/Canada: Traders Face Uncertainty Over Iran Conflict, Says BOC's Macklem

Dow Jones
·
Mar 05

Altimmune Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
Mar 03

Altimmune to Join Leerink, Citizens, Jefferies and Barclays Investor Conferences

Reuters
·
Mar 02

Altimmune Inc. updates financial calendar with upcoming earnings report and conference call

Reuters
·
Feb 26

Altimmune Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
Feb 23

Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis

GlobeNewswire
·
Feb 17

Altimmune initiated with a Buy at Titan Partners

TIPRANKS
·
Feb 13

Novo Nordisk Warns on Profits and Sales Amid Trump Drug Price Crackdown

Reuters
·
Feb 04

Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock

THOMSON REUTERS
·
Jan 30

Barclays Initiates Coverage on Altimmune With Overweight Rating, $20 Price Target

MT Newswires Live
·
Jan 28

Altimmune (ALT) Raises $75M to Boost Obesity Drug Pipeline

TIPRANKS
·
Jan 28

Altimmune prices $75M registered direct offering

TIPRANKS
·
Jan 28

Altimmune Raises $75 Million in Direct Offering of Shares and Pre-Funded Warrants

Reuters
·
Jan 28

Altimmune initiated with an Overweight at Barclays

TIPRANKS
·
Jan 28

Libevitug Approved in China as First-in-Class Hepatitis D Treatment

prnewswire
·
Jan 27

Altimmune (ALT) Valuation Check After Pemvidutide’s FDA Breakthrough Therapy Designation

Simply Wall St.
·
Jan 27

Altimmune (ALT) Is Up 29.7% After FDA Breakthrough Tag for Pemvidutide in MASH Trial

Simply Wall St.
·
Jan 26

Altimmune call volume above normal and directionally bullish

TIPRANKS
·
Jan 23

CCL Industries to Acquire ALT Technologies, Expanding Automotive Safety Business

TIPRANKS
·
Jan 16